Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

June 18, 2018

Study Completion Date

June 18, 2018

Conditions
Infectious Peritonitis
Interventions
DRUG

Dalbavancin via Intravenous Administration

Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.

DRUG

Dalbavancin via Intraperitoneal Administration

Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02940730 - Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients | Biotech Hunter | Biotech Hunter